New marker, new target in Ewing's sarcoma
Ewing's sarcoma is a bone cancer commonly diagnosed in about 250 U.S. teenagers per year. If early chemotherapy is effective, improvement can be durable. But for children and teens who respond poorly to a first attempt at chemotherapy or if the disease spreads, long-term survival can be less than 10 percent.
A University of Colorado Cancer Center study published this week in the journal Molecular Cancer Research shows an important difference that may explain why some respond and some don't: the existence of high levels of the protein EYA3.
"First, levels of EYA3 could be a tool in offering an accurate prognosis and choosing how aggressively to treat Ewing's Sarcoma, and second we hope that by lowering levels of EYA3, we could help increase the effectiveness of existing therapies for Ewing's sarcoma," says Tyler Robin, PhD, first author of the recent paper.
Researchers recently defined the role of EYA3 as a DNA repair molecule and Tyler showed that EYA3 has a similar repair role in Ewing's sarcoma high levels of EYA3 help the tissue survive during and recover after treatment with chemotherapy. Importantly, when Robin knocked down EYA3 in Ewing's sarcoma cells, they became sensitized to chemotherapy.
"The genetic mutation that creates Ewing's sarcoma also leads to high levels of EYA3," says Heide Ford, PhD, investigator at the CU Cancer Center and associate professor in the CU School of Medicine department of ob/gyn, and the paper's senior author.
The mutation Ford refers to and that creates Ewing's sarcoma is the fusion of a gene from chromosome 22 to a gene in chromosome 11. Known as a EWS/FLI translocation, this mutation turns off a cell's ability to make another, intermediate step known as miR-708 a molecule that helps to decide what parts of the genome do and don't get read and manufactured into proteins. In healthy tissue, miR-708 turns off the production of EYA3; in Ewing's sarcoma, miR-708 is down and so EYA3 is up.
"Our next step is to test small molecule inhibitors against EYA3 to determine which inhibitors best sensitize Ewing's sarcomas to chemotherapy," says Ford.
Robin and Ford hope that recognizing EYA3 levels, reducing these levels directly, or intervening in the steps that lead to its over-production will help predict outcomes, make decisions about existing treatments, and eventually lead to new treatments for Ewing's sarcoma.
Journal reference:
Molecular Cancer Research
Provided by
University of Colorado Denver
-
Bone cancer treatment ineffective, despite promising laboratory data
Nov 10, 2008 |
not rated yet |
0
-
New Hope for Deadly Childhood Bone Cancer
Aug 31, 2009 |
not rated yet |
0
-
Targeting the Ewing sarcoma family of tumors
Jul 01, 2011 |
not rated yet |
0
-
Study finds therapeutic targets for rare cancer in children
Sep 01, 2010 |
not rated yet |
0
-
Figitumumab has anti-tumor activity in Ewing's sarcoma
Dec 23, 2009 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013
-
If you became brain-dead, would you want them to pull the plug?
May 17, 2013
-
MRI bill question
May 15, 2013
-
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013
-
Alcohol and acetaminophen
May 13, 2013
-
Marie Curie's leukemia
May 13, 2013
- More from Physics Forums - Medical Sciences
More news stories
Older prostate cancer patients should think twice before undergoing treatment
Older prostate cancer patients with other underlying health conditions should think twice before committing to surgery or radiation therapy for their cancer, according to a multicenter study led by researchers in the UCLA ...
Cancer
12 hours ago |
not rated yet |
0
|
Two radiotherapy treatments show similar morbidity, cancer control after prostatectomy
Intensity-modulated radiation therapy has become the most commonly used type of radiation in prostate cancer, but research from the University of North Carolina suggests that the therapy may not be more effective than older, ...
Cancer
14 hours ago |
not rated yet |
0
The compound in the Mediterranean diet that makes cancer cells 'mortal'
New research suggests that a compound abundant in the Mediterranean diet takes away cancer cells' "superpower" to escape death. By altering a very specific step in gene regulation, this compound essentially re-educates cancer ...
Cancer
14 hours ago |
4.8 / 5 (12) |
2
|
CT radiation risk less than risk of examination indicator
(HealthDay)—For young adults needing either a chest or abdominopelvic computed tomography (CT), the short-term risk of death from underlying morbidity is greater than the long-term risk of radiation-induced ...
Cancer
15 hours ago |
not rated yet |
0
Team finds mechanism linking key inflammatory marker to cancer
In a new study described in the journal Oncogene, researchers reveal how a key player in cell growth, immunity and the inflammatory response can be transformed into a primary contributor to tumor growth.
Cancer
21 hours ago |
not rated yet |
0
|
Study puts Huntington's disease trials on TRACK
(Medical Xpress)—A three-year multinational study has tracked and detailed the progression of Huntington's disease (HD), predicting clinical decline in people carrying the HD gene more than 10 years before ...
No new H7N9 cases in China for a week
No new human cases of the H7N9 virus have been recorded in China for a week, national health authorities said, for the first time since the outbreak began in March.
Nobel laureate plays down flu pandemic scaremongering
A Nobel prize-winning scientist Tuesday played down "shock-horror scenarios" that a new virus strain will emerge with the potential to kill millions of people.
Genetic predictors of postpartum depression uncovered
Johns Hopkins researchers say they have discovered specific chemical alterations in two genes that, when present during pregnancy, reliably predict whether a woman will develop postpartum depression.
New immune system discovered
(Medical Xpress)—A research team, led by Jeremy Barr, a biology post-doctoral fellow, unveils a new immune system that protects humans and animals from infection.
Scientists identify molecular trigger for Alzheimer's disease
Researchers have pinpointed a catalytic trigger for the onset of Alzheimer's disease – when the fundamental structure of a protein molecule changes to cause a chain reaction that leads to the death of neurons ...